Table III.
First author, year (reference)
country |
Design | Participants (Treatment Group) | Mean participants characteristics and age (year) | Exclusion criteria | Other participant demographics and comments |
---|---|---|---|---|---|
Topo et al. 2009 (40) Italy |
Placebo-controlled, parallel clinical trial | 43 (23) | IVF (in vitro fertilization) patients (27-37) | No information given | Healthy sedentary |
Willoughby et al. 2013 (49) USA |
Randomized, double-blind, placebo-controlled, parallel clinical trial | 20 (10) | Resistance trained men (resistance training for 1 year before the study) (22.8 ±4.67) |
Consumption any nutritional supplements (excluding multivitamin) such as creatine monohydrate, nitric oxide-stimulating, hydroxy-β-methylbutyrate, or pharmacologic agents such as anabolic steroids 3 months before the study | Height, total body mass, all participants passed a mandatory medical screening |
Bloomer et al. 2015 (50) USA |
Parallel clinical trial | 5 (One Serving) 5 (Two Servings) |
Physically active men 40.8±1.0 (One Serving) 43.4±4.2 (Two Servings) | Smokers, history of cardiovascular or metabolic disease (including hypertension), using hormonal replacement or dietary supplements designed to increase hormone production | Age, height, body, weight, body mass index, waist circumference, hip circumference |
Melville et al. 2015 (51) Australia |
Randomize, double-blind, placebo-controlled, parallel clinical trial | 24 (8) two groups | Resistance-trained men (minimum of two years’ experience in resistance training) (24.5 ± 3.2) |
Acute or chronic medical conditions, consume any ergogenic or testosterone booting supplements | Training age, height, body mass, 1 RM bench |